Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
Talia Golan(Sheba Medical Center), Hedy L. Kindler(University of Chicago), Michael J. Hall(Fox Chase Cancer Center), Hana Algül(TUM Klinikum), David McGuinness(Université Paris Cité), Anke Reinacher‐Schick(Ruhr University Bochum), Karen Cui(Université Paris Cité), Katia Schlienger(United States Military Academy), Giampaolo Tortora(University of Naples Federico II), Dirk Arnold(Asklepios Klinik Altona), Do‐Youn Oh(Seoul National University Hospital), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Daniel Hochhauser(Royal London Hospital), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Joon-Oh Park(Université Paris Cité), Michele Reni(San Raffaele University of Rome), Pascal Hammel(Université Paris Cité), Gershon Y. Locker(AstraZeneca (United States))
Cited by 2,206
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k